Dr. Mike Krams, Chief Quantitative Medicine Officer at Exscientia plc discusses the first clinical trial application (CTA) approval in Europe for IGNITE-AI, a Phase 1/2 trial studying EXS-21546 (‘546) – an A2A receptor antagonist in combination with anti-PD-1 therapy – in patients with immunotherapy relapsed or refractory renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC). He talks about how this trial will further translate the scientific potential for A2A receptor antagonists into clinical results.
Dr. Krams leads clinical development strategy for Exscientia’s portfolio of investigational medicines with a focus on innovative clinical trial design and improved methods of patient selection to maximise clinical success and patient benefit. He is based at Exscientia’s precision medicine centre of excellence in Vienna, Austria. Prior to joining Exscientia, Dr. Krams most recently led the Quantitative Sciences group at Janssen R&D, bringing together approximately 500 statisticians, pharmacologists and modellers to enable efficient decision-making in various aspects of drug development. Earlier, he was Vice President of Adaptive Trials and Applied Program Strategies at Wyeth. Dr. Krams holds an M.D. from the University of Munich.